The Cancer Letter

Inside information on cancer research and drug development

Drugs & Targets

Array BioPharma reaches agreement with Novartis PharmaAG

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

Array BioPharma Inc. reached an agreement with Novartis Pharma AG to acquire worldwide rights to encorafenib (LGX818), a BRAF inhibitor currently in phase III development. This agreement is conditional on the closing of transactions announced by Novartis and GlaxoSmithKline PLC on April 22, 2014, which are expected to close in the first half of 2015, and the agreement remains subject to the receipt of regulatory approvals.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Sponsored

Harnessing innovation: The next frontier in surgical oncology

The field of surgical oncology has undergone transformative advancements over the last decade. From refining minimally invasive techniques to leveraging immunotherapy and viral oncolytics, our collective goal remains the same: improving patient outcomes while reducing treatment burden. At City of Hope, we have prioritized accelerating the translation of laboratory discoveries into clinical applications, and nowhere is this more evident than in our work with oncolytic viruses, remote surgery, and the integration of AI in surgical decision-making.
By Yuman Fong
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account